Showing 2051-2060 of 5275 results for "".
- GW Earns Skin Smart Campus Recognitionhttps://practicaldermatology.com/news/GW-Earns-Skin-Smart-Campus-Recognition/2471093/The National Council on Skin Cancer Prevention recognized George Washington University as a Skin Smart Campus for its ongoing commitment to fostering a safe and healthy learning environment, with a focus on skin cancer prevention and UV safety, the university announced. The Skin Smart Camp
- DELTA TEEN: Positive Results for Delgocitinib in Adolescent Chronic Hand Eczemahttps://practicaldermatology.com/news/delta-teen-positive-results-for-delgocitinib-in-adolescent-chronic-hand-eczema/2471096/Phase 3 data from the DELTA TEEN trial demonstrated that Anzupgo® (delgocitinib) cream achieved significant improvements in symptoms of moderate to severe chronic hand eczema (CHE) in adolescents aged 12–17, according to a news release from the manufacturer. The DELTA TEEN trial was a 16-w
- Baricitinib Enhances Phototherapy Efficacy in Adults with Active Vitiligohttps://practicaldermatology.com/news/baricitinib-enhances-phototherapy-efficacy-in-severe-atopic-dermatitis/2471046/Baricitinib combined with narrowband UV-B achieved a modest reduction in disease severity in adults with severe, active nonsegmental vitiligo, but did not meet the prespecified threshold for sufficient repigmentation, new research revealed. The trial enrolled 49 adul
- Study: Safety Signals Emerge for IL-23 and IL-12/23 Inhibitors in Psoriasis Treatmenthttps://practicaldermatology.com/news/safety-signals-emerge-for-il-23-and-il-1223-inhibitors-in-psoriasis-treatment/2470971/A new analysis of psoriasis patients indicates an emergence of new safety signals associated with interleukin-23 (IL-23) inhibitors and the IL-12/23 inhibitor ustekinumab. Researchers on the study analyzed 41.4 million adverse event (AE) reports from the FDA Adverse Event Reporting System
- Gene Expression Patterns Linked to Psoriasis Severity and Treatment Responsehttps://practicaldermatology.com/news/gene-expression-patterns-linked-to-psoriasis-severity-and-treatment-response/2470916/Gene expression abnormalities not only reflect the severity of psoriatic lesions but also predict treatment response, according to a recent study published in JID Innovations. Researchers on the study analyzed gene expression profiles in psoriatic skin using Gene Set Variation Ana
- GHG Audit Shows Key Emission Sources in Dermatology Practicehttps://practicaldermatology.com/news/ghg-audit-shows-key-emission-sources-dermatology-practice/2470894/A new study has identified scope 3 emissions, particularly purchased goods and services, as the largest contributor to the carbon footprint of an outpatient dermatology clinic, accounting for 51.1% of total greenhouse gas (GHG) emissions. The research, conducted at a University of Pennsylv
- Practical Dermatology Names Dr. Lisa Swanson Associate Medical Editorhttps://practicaldermatology.com/news/practical-dermatology-names-dr-lisa-swanson-associate-medical-editor/2470863/Elizabeth (Lisa) Swanson, MD, FAAD, has accepted the position of Associate Medical Editor of Practical Dermatology, the journal announced. In this capacity, Dr. Swanson will work closely with Chief Medical Editor Neal Bhatia, MD, FAAD, to provide direction for Practical Dermat
- Skin Cancer Foundation Names New Executive Directorhttps://practicaldermatology.com/news/skin-cancer-foundation-names-new-executive-director/2470856/The Skin Cancer Foundation (SCF), a national nonprofit organization that is committed to decreasing the incidence and mortality of the world’s most common cancer through public education, announced that it has appointed Becky Kamowitz to the role of executive director. Kamowitz has worked
- VYNE Therapeutics Completes Enrollment for Phase 2b Trial of VYN201 in Nonsegmental Vitiligohttps://practicaldermatology.com/news/vyne-therapeutics-completes-enrollment-phase-2b-trial-vyn201-nonsegmental-vitiligo/2470854/VYNE Therapeutics Inc. has finalized enrollment for its Phase 2b trial of VYN201, a once-daily topical gel for nonsegmental vitiligo, with initial data from the 24-week double-blind portion anticipated in mid-2025, according to a news release from the manufacturer. The randomized, double-b
- Method Review: A Closer Look at Cryo-EM’s Impact on Dermatologyhttps://practicaldermatology.com/news/method-review-a-closer-look-at-cryo-ems-impact-on-dermatology/2470806/A recent method review in the Journal of Investigative Dermatology points to the potential of cryogenic electron microscopy (cryo-EM) in dermatological research. According to the authors, advanced imaging technology enables atomic-resolution visualization of macromolecules in thei